Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	149.61	29.16	99.92
Cash & Short-Term Investments	149.61	29.16	99.92
Cash Growth	49.73%	-70.82%	-
Prepaid Expenses	4.25	4.95	6.23
Total Current Assets	153.96	34.11	106.15
Property, Plant & Equipment	30.93	34.98	41.23
Other Long-Term Assets	4.29	2.41	2.58
Total Assets	192.48	71.5	149.96
Accounts Payable	1.02	2.02	1.59
Accrued Expenses	11.7	9.81	14.87
Current Portion of Leases	4.62	4.49	4.32
Total Current Liabilities	17.56	16.32	20.78
Long-Term Debt	51.75	20.08	-
Long-Term Leases	22.8	25.05	27.73
Total Liabilities	93.11	61.45	48.51
Common Stock	0.02	0.02	0.02
Additional Paid-In Capital	29.32	21.82	12.79
Retained Earnings	-313.88	-395.69	-295.27
Total Common Equity	-284.53	-373.85	-282.46
Shareholders' Equity	99.37	10.05	101.44
Total Liabilities & Equity	192.48	71.5	149.96
Total Debt	79.16	49.62	32.06
Net Cash (Debt)	70.45	-20.47	67.86
Net Cash Per Share	3.08	-0.93	3.50
Filing Date Shares Outstanding	23.43	22.39	19.38
Total Common Shares Outstanding	23.43	22.39	19.38
Working Capital	136.4	17.79	85.37
Book Value Per Share	-12.15	-16.69	-14.58
Tangible Book Value	-284.53	-373.85	-282.46
Tangible Book Value Per Share	-12.15	-16.69	-14.58
Machinery	-	16.47	16.08
Construction In Progress	-	0.06	-
Leasehold Improvements	-	5.36	5.33

Source: S&P Capital IQ. Standard template. Financial Sources.